APOA5 and aortic stenosis: Dyslipidemia linked to Lipoprotein a (LPA)-associated APOA5 has been detected in AS (74), with the reduction of LPA levels via PSCK9 inhibitors constituting promising therapeutic avenues for AS treatment (47–49).